RxSight reports Q4 adjusted EPS 3, consensus (1c)

Reports Q4 revenue $40.21M, consensus $40.23M. “The progress we’ve made over the past year has strengthened our conviction that adjustability has the potential to transform the premium cataract market, and that we are still in the early stages of realizing this vision,” said Ron Kurtz, CEO and president of RxSight (RXST). “As we look ahead to 2025 and beyond, we are excited by the opportunity to further expand adoption globally, advance our technology, and continue delivering exceptional outcomes for both patients and practices.”